Sarah Boyce - Jun 12, 2024 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
President and CEO, Director
Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Stock symbol
RNA
Transactions as of
Jun 12, 2024
Transactions value $
-$11,216,306
Form type
4
Date filed
6/14/2024, 06:58 PM
Previous filing
Jun 5, 2024
Next filing
Jun 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $124K +100K +89.19% $1.24* 212K Jun 12, 2024 Direct F1
transaction RNA Common Stock Sale -$3.57M -100K -47.14% $35.73 112K Jun 12, 2024 Direct F1, F2
transaction RNA Common Stock Options Exercise $204K +164K +146.48% $1.24* 276K Jun 13, 2024 Direct F1
transaction RNA Common Stock Sale -$6.58M -164K -59.43% $40.08 112K Jun 13, 2024 Direct F1, F3
transaction RNA Common Stock Options Exercise $44.4K +35.8K +31.9% $1.24* 148K Jun 14, 2024 Direct F1
transaction RNA Common Stock Sale -$1.43M -35.8K -24.19% $40.08 112K Jun 14, 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -100K -12.24% $0.00 717K Jun 12, 2024 Common Stock 100K $1.24 Direct F1, F5
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -164K -22.91% $0.00 553K Jun 13, 2024 Common Stock 164K $1.24 Direct F1, F5
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -35.8K -6.47% $0.00 517K Jun 14, 2024 Common Stock 35.8K $1.24 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on June 9, 2023 by the Reporting Person.
F2 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $37.57. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.35. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.01 to $40.22. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 All unexercised shares subject to the option are fully vested and exercisable as of the date hereof.